Nerve Health · Small Fiber Neuropathy Treatment
Most small fiber neuropathy treatment does not fail because the drugs are bad. It fails because nobody explained what the drugs were ever capable of doing.
✦ The Short Version
Effective small fiber neuropathy treatment means three things running together: finding and addressing the cause, using pain medications at real therapeutic doses when they fit the job, and supporting the metabolic environment the nerve is trying to recover inside. Most plans only ever run the middle one, which is why they manage symptoms without doing much to help the nerve recover.
The honest ceiling on the drugs. Four drug classes carry real evidence in neuropathic pain. Pooled across every published trial, roughly one in six to one in eight patients reaches 50 percent pain relief on any of them. Knowing that up front changes how you interpret a disappointing result. And most medication "failures" are dosing failures: a patient who stopped gabapentin at 300mg never reached a therapeutic dose.
What the trials actually showed. IVIG has now been tested in a proper randomized trial for idiopathic small fiber neuropathy. Forty percent improved on IVIG. Thirty percent improved on saline. The difference was not significant. Scrambler therapy has published data in this condition, and it consists of three patients.
And the part that reorders everything else: the interventions that have actually increased nerve fiber density in living humans are metabolic, not pharmaceutical. That is the ceiling every drug on this page is working underneath.
This post covers treatment. If you are still working out whether you have small fiber neuropathy, or what is causing it, start with the diagnostic pillar on why a normal EMG does not rule out nerve damage.
Dr. Michael Fitzmaurice, MD
Fellowship-Trained Peripheral Nerve Surgeon & Metabolic Health Educator · About Dr. Fitzmaurice
"I spent years operating on peripheral nerves, more than three thousand procedures, and one thing the tissue taught me is that a treatment is only as good as the problem it was aimed at. Most people with small fiber neuropathy are handed a drug built to quiet a pain signal, then told there is nothing left to try when it does not fix the nerve. Those are two different jobs, and only one of them is being done."
There is one number that reorganizes this entire subject, and almost nobody with small fiber neuropathy is ever shown it. In the largest pooled analysis of neuropathic pain drugs ever assembled, 229 randomized trials in total, the number needed to treat for gabapentin was 7.2. Seven patients take it. One gets half their pain back that they would not have gotten from a sugar pill.
That is not a bad drug. That is a well-studied drug performing exactly as designed, which is to dampen an overactive pain signal in a nerve that is still under attack. It was never built to stop the attack.
If you have already cycled through two of these medications and been told there is nothing more to try, the conclusion is premature, but not for the reason most articles suggest. It is not that a better drug is waiting. It is that the treatment plan has been running on one layer when it needs to run on four, and the layer with the most leverage is not the prescription pad. Getting that distinction right matters, because many patients write off treatment far too early when the real problem was an incomplete plan rather than true treatment failure.
What follows is the full treatment landscape for small fiber neuropathy: first-line medications, what counts as an adequate dose and trial length, when combination therapy makes sense, what the IVIG and neuromodulation evidence actually shows, which metabolic interventions and nutrient doses support nerve recovery, and how to prepare for your next clinic appointment.
What You Will Learn
➤ What the number needed to treat really means for gabapentin, pregabalin, duloxetine, and the tricyclics
➤ The dose and duration that make a medication trial legitimate, and why most trials are abandoned early
➤ When combining two agents makes sense, and which combination to avoid
➤ What the randomized IVIG trial in idiopathic small fiber neuropathy actually found
➤ Where scrambler therapy, TENS, and spinal cord stimulation honestly sit on the evidence ladder
➤ Why the drug tier has a ceiling, and the only thing shown to raise it in human beings
➤ How to evaluate a nerve supplement by dose rather than by ingredient list, and the one B vitamin where more is actively worse
➤ Exactly what to say at your next appointment when a medication has not worked
Before Any of This: The One Thing Treatment Depends On
Everything below assumes a completed workup. That is not a formality.
Small fiber neuropathy is a description of which fibers are failing. It is not an explanation of why. Something produced it, and the identity of that something determines whether disease-modifying treatment even exists in your case. Dysglycemia, including the prediabetic range that most people are told not to worry about, is the most common driver. Diabetes is the single most common cause, metabolic syndrome contributes an increased risk of its own, and hyperlipidemia is an important risk factor. Nearly half of cases labeled idiopathic turn out to show abnormal blood sugar handling on proper testing.
Beyond glucose, vitamin B12 deficiency, Sjogren's syndrome, sarcoidosis, celiac disease, thyroid dysfunction, transthyretin amyloidosis, Fabry disease, sodium channel variants, HIV, and certain medications or toxin exposures each carry a different treatment target. That is the entire reason the workup comes before the prescription.
If your workup did not include a two-hour oral glucose tolerance test, methylmalonic acid alongside your B12, an autoimmune screen, and a skin biopsy measuring nerve fiber density, then the most common causes of this condition have not been excluded. The full diagnostic sequence is covered in the pillar post. Come back here once it is done, because treatment decisions made before that point are guesswork.
✦ KEY TAKEAWAY — Every medication on this page is symptom control. Whether you also have disease-modifying options depends entirely on what your workup found. That is why the workup comes first, not because it is protocol.
Not sure where your nerve health stands?
Take the free 5-minute Nerve Health Risk Assessment. It was designed by a peripheral nerve surgeon and shows which factors may be affecting your nerves.
Take the Free Assessment →Small Fiber Neuropathy Treatment With First-Line Medications, and What the Response Rates Honestly Look Like
Four drug classes carry a strong first-line recommendation for neuropathic pain: tricyclic antidepressants, serotonin-noradrenaline reuptake inhibitors, pregabalin, and gabapentin. Understanding how well they work requires one piece of vocabulary that patients are rarely given.
Number needed to treat, or NNT, is how many patients must take a drug for one additional person to get a defined benefit beyond what placebo produced. In neuropathic pain research that benefit is usually 50 percent pain reduction. An NNT of 7 means seven people take the drug and one of them gets half their pain back because of it. Lower is better.
The reference analysis for this field pooled 229 studies through the International Association for the Study of Pain's neuropathic pain interest group. Its figures were: serotonin-noradrenaline reuptake inhibitors 6.4 (95% CI 5.2 to 8.4), gabapentin including extended-release forms 7.2 (5.9 to 9.2), pregabalin 7.7 (6.5 to 9.4), and high-concentration capsaicin patches 10.6 (7.4 to 19.0). Tricyclic antidepressants came in lower than all of these, with the commonly cited pooled figure around 3.6 (Finnerup et al., Lancet Neurology, 2015).
Seven patients take gabapentin. One gets half their pain back because of it. That is not failure, it is what a pain-signal drug does to a nerve that is still being damaged.
You will see lower figures quoted elsewhere: around 4 for the gabapentinoids, 4.2 for pregabalin in narrower analyses, and 5.2 for duloxetine when the population is restricted to painful diabetic neuropathy specifically. Those generally come from older or narrower syntheses, or from a single indication rather than neuropathic pain as a whole. The figures above are the current pooled estimates from the largest and most rigorous synthesis available, and they are the ones worth planning around.
That same analysis estimated publication bias was overstating treatment effects by roughly 10 percent, and found that studies published in journals reported larger effects than unpublished ones. The real-world numbers are, if anything, slightly worse than the published ones.
None of this is an argument against taking these pain medications. Burning neuropathy pain is disabling and deserves treatment. It is an argument for interpreting a partial response correctly instead of concluding you are a hopeless case. One point worth clearing up while we are here: antidepressant medications treat nerve pain through pain pathways directly, and they work in patients who are not depressed. Duloxetine is commonly used as a second-line option for nerve pain for exactly that reason. Being offered one is not a suggestion that the pain is in your head.
What an Adequate Medication Trial Actually Looks Like
This is where most treatment plans quietly fail, and it has nothing to do with the drug.
A medication trial is only meaningful at a therapeutic dose, sustained long enough to work. In practice, a large share of patients stop at a starting dose after a week because of side effects that would have settled, then carry that drug forward on their chart as a failure. It was not a failure. It was never a trial.
The dosing ranges below are the ones used in the published literature. They are here so you can recognize where you are on the curve, not so you can adjust anything yourself. Your prescriber sets your dose.
Most drugs are abandoned on the early part of the curve, well below the range where the trials found benefit.
Gabapentin is typically started at 300mg at bedtime and titrated upward every three to seven days, with the effective range in trials generally falling between 1,800mg and 3,600mg per day, divided across three doses. Absorption is saturable, meaning larger individual doses are absorbed progressively less efficiently, which is why it is split. Dose is reduced in kidney impairment. Sedation and cognitive dulling are the dose-limiting effects and usually improve over one to two weeks at a stable dose.
Pregabalin has more predictable, linear absorption and can be titrated faster. Trials generally used 300mg to 600mg per day divided into two doses, often starting at 75mg twice daily, or lower in older adults. It tends to reach effect sooner than gabapentin. Average efficacy between the two is similar.
Duloxetine works through descending inhibitory pathways in the spinal cord rather than at the peripheral nerve. Trials typically used 60mg daily, sometimes started at 30mg for a week to limit early nausea, with some protocols going to 120mg. It is often the better first choice when disrupted sleep, anxiety, or low mood travel alongside the pain, which in this population they frequently do. It should be tapered rather than stopped abruptly.
Nortriptyline and amitriptyline carry the best numbers and the worst tolerability. Typical trial dosing starts at 10mg to 25mg at bedtime and titrates slowly. Nortriptyline is generally better tolerated than amitriptyline. Anticholinergic effects, morning grogginess, orthostatic drops, and cardiac conduction considerations in older adults are the limiting factors, and a baseline ECG is reasonable in anyone over 65 or with cardiac history. Low-dose nighttime use in a patient whose central complaint is that burning feet destroy their sleep can be worth a great deal even when daytime pain relief is modest.
How long to give it. Reaching target dose typically takes two to four weeks of titration. Then the drug needs roughly four more weeks at that dose before the result means anything. A drug abandoned inside three weeks has not been tested.
✦ Practical Tool — Is This a Real Medication Trial?
Before writing off any drug, check all four. If any one is missing, that drug has not actually failed yet.
1. Dose. Did you reach the therapeutic range, or did you stop during titration because of early side effects?
2. Duration. Did you hold that dose for at least four weeks after reaching it?
3. Consistency. Were you taking it on schedule, including the divided doses, or intermittently when pain was bad? These drugs do not work as needed.
4. Measurement. Did you track pain on a 0 to 10 scale before and during, or are you comparing against memory? Written pain scores over time are more reliable than memory for judging treatment response, and a real 30 percent improvement often feels like nothing until it is written down.
✦ KEY TAKEAWAY — Most patients who say a nerve pain medication did nothing stopped it during titration. A starting dose held for ten days is not a failed trial, and it should not close the door on that drug forever.
When One Drug Is Not Enough: Combinations and Sequencing
If a first agent produces partial relief at a real dose, the next step is usually not abandoning it. Combining agents from different classes has trial support in neuropathic pain, and combination therapy is a standard part of specialized pain management when a single drug class delivers only incomplete benefit. The logic is mechanistic: a gabapentinoid acts on calcium channel signaling at the nerve terminal while a tricyclic or SNRI acts on descending inhibition from the brainstem. Different points in the pathway, additive effect, and often lower doses of each with better tolerability than pushing one drug to its ceiling.
The pairing to be careful with is duloxetine plus a tricyclic. Both raise serotonin, and combining them raises the risk of serotonin toxicity. That combination is generally avoided outside of specialist supervision.
Topical treatments combine cleanly with anything, because they carry almost no systemic burden. That is their real advantage, and it matters most for a patient already sedated on two oral drugs.
One honest correction on topicals. Lidocaine 5 percent patches and capsaicin are widely described online as reliably effective for localized burning. The evidence is more uneven. High-concentration 8 percent capsaicin, applied in office, works by defunctionalizing TRPV1 receptors and has a pooled NNT of 10.6, which is real but modest. Capsaicin cream can also relieve localized neuropathic pain, though expectations should stay modest there too. For the lidocaine patch, that same meta-analysis could not determine an NNT at all because the trial data were insufficient. Worth trying, with accurate expectations, not the underused breakthrough they are often presented as.
What about opioids and tramadol. Standard over the counter options do very little to treat neuropathic pain, which is why targeted nerve pain medications exist at all. Opioids sit third-line in every major guideline for a reason: efficacy in neuropathic pain is modest, long-term data are poor, and the harm profile is real. Tramadol is the better-studied option in this category and can be effective for neuropathic pain, but because it can be addictive its role stays limited. None of these address a nerve that is still being damaged.
IVIG for Small Fiber Neuropathy: What the Randomized Trial Actually Found
IVIG comes up constantly in patient communities, usually attached to a dramatic individual story. The controlled evidence tells a different story, and anyone about to advocate for this treatment deserves to see it first.
The first double-blind randomized placebo-controlled trial of IVIG in idiopathic small fiber neuropathy enrolled 60 Dutch patients with skin-biopsy-proven disease. They received a 2 g/kg loading dose followed by three maintenance infusions of 1 g/kg at three-week intervals, or matched saline placebo. At 12 weeks, 40 percent of the IVIG group had at least a one-point drop in pain score, compared with 30 percent of the placebo group. The difference was not statistically significant (p = 0.588, odds ratio 1.56, 95% CI 0.53 to 4.53). No prespecified secondary outcome favored IVIG either, including general well-being, autonomic symptoms, functioning, or disability. The trial was graded Class I evidence (Geerts et al., Neurology, 2021).
Look closely at those numbers, because they explain the anecdotes. Thirty percent of patients improved on saline. When four in ten improve on an expensive infusion and three in ten improve on salt water, compelling individual success stories are mathematically guaranteed. They are also uninformative about whether the drug works.
Where the Immune Conversation Is Still Legitimate
That trial studied idiopathic small fiber neuropathy, meaning no cause was found. It does not address SFN driven by a confirmed autoimmune disease, and the distinction matters clinically. In sarcoidosis, Sjogren's syndrome, or a defined connective tissue disease with small fiber involvement, immunomodulation aimed at the underlying condition is a real and appropriate conversation. In immune-mediated small fiber neuropathy the immune system is driving the injury, which means immunotherapy is addressing the disease process rather than chasing the symptom. The target there is the disease, not the pain.
Antibody markers such as TS-HDS and FGFR3 appear in observational reports as possible predictors of immune-responsive SFN. They remain hypothesis-generating. They are not validated predictors of who responds, and they should not be presented to a patient as though they were.
The question to bring to your neurologist is precise: has an autoimmune etiology been ruled in or ruled out, and by which tests? If it has been ruled in, immunotherapy is on the table. If your SFN is genuinely idiopathic, the best available trial says IVIG is unlikely to help you.
Neuromodulation: Scrambler Therapy, TENS, and Spinal Cord Stimulation
Scrambler Therapy
Scrambler therapy is FDA-cleared cutaneous electrostimulation that feeds synthetic non-pain signals along the same pathways carrying the pain signal, with the aim of retraining central processing rather than suppressing it chemically. It has generated legitimate interest in chemotherapy induced peripheral neuropathy.
In small fiber neuropathy specifically, the published experience amounts to a three-patient report from Johns Hopkins. One patient had significant initial improvement, one had temporary benefit requiring repeat sessions, and one got roughly an hour of relief (Sanchez and Smith, Pain Medicine, 2024).
Three patients. Anyone quoting an 80 to 90 percent response rate for scrambler therapy in SFN is borrowing a figure from broader chronic pain populations and applying it to a condition where it has not been studied. It may still be worth trying in a refractory case, and its safety profile is favorable. It should be tried with accurate expectations and a defined stopping point.
TENS
Transcutaneous electrical nerve stimulation, or TENS, is inexpensive and low-risk, with no SFN-specific trial data behind it. Its use here is extrapolated from wider neuropathic pain care, and it is often paired with physical therapy for symptom control and gait work. Patients with muscle weakness, mobility limits, or balance problems may also benefit from physiotherapy and supportive devices to improve strength and mobility. Reasonable to try precisely because the downside is close to zero.
Spinal Cord Stimulation
An implanted device with real procedural risk and no SFN-specific evidence base. It belongs in the conversation only after multiple drug classes and conservative measures have genuinely failed at adequate doses, under specialist pain management, and typically after a trial lead placement. Depending on the pain pattern, procedural options such as nerve blocks may enter that same discussion before or alongside any decision to implant.
✦ KEY TAKEAWAY — The evidence ladder for neuromodulation in small fiber neuropathy is short: TENS is cheap and untested, scrambler has three published patients, and spinal cord stimulation has none. That does not make them worthless. It means the conversation should be honest about what is known.
Why the Drug Tier Has a Ceiling
Here is the part that explains every modest number on this page.
Medications treat the pain signal, but they do not reverse the loss of small nerve fibers. Small fiber neuropathy treatment still depends on identifying and addressing the underlying cause, with medications used to relieve the neuropathic symptoms while that work happens. When the process damaging the nerve is still running, the drug is holding a line against something that keeps advancing, and the best pooled NNT in the field is what that looks like in the data.
The contrast is instructive. The TopCSPN trial randomized 132 patients with cryptogenic sensory peripheral neuropathy and metabolic syndrome to topiramate or placebo, with nerve fiber density and neuropathy-specific quality of life as co-primary outcomes. Topiramate was noninferior but not superior on either measure in the intention-to-treat analysis. It appeared to slow the expected decline in fiber density without reaching statistical superiority (Smith et al., JAMA Neurology, 2023).
That trial was deliberately built around a metabolic-syndrome population, because that is where the driver sits. A well-designed, adequately powered pharmaceutical trial aimed squarely at the right patients still could not clearly beat placebo on the tissue outcome.
The interventions that have moved that tissue outcome in humans were metabolic. Which brings us to the layer that actually raises the ceiling.
Why I formulated NeuroAxis
Medications work on the pain signal. The layers below work on the environment the nerve lives in, and that is the part I built NeuroAxis around. Nerves depend on several nutritional pathways at once: energy production, antioxidant defense, and myelin support. NeuroAxis combines R-alpha-lipoic acid, methylcobalamin, benfotiamine, and acetyl-L-carnitine with other researched nutrients in a single multi-pathway formula.*
Every order also includes the 160-page NeuroAxis Protocol, my guide to the nutrition and lifestyle pillars that come before any supplement.
See NeuroAxis + the 160-Page Protocol →*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
The Metabolic Layer: The Only Thing Shown to Move the Tissue
Lifestyle advice usually arrives as a courtesy at the end of an appointment, delivered in a tone that signals nobody expects you to act on it. In metabolically driven small fiber neuropathy it is the most powerful intervention on this page, and there are two human studies that make that a statement of fact rather than a philosophy.
Thirty-two patients with impaired glucose tolerance and neuropathy underwent one year of individualized diet and exercise counseling modeled on the Diabetes Prevention Program. Proximal intraepidermal nerve fiber density improved by 1.4 fibers per millimeter (p < 0.004), and the degree of improvement correlated with reduced neuropathic pain (p < 0.05) and with improvement in sural sensory amplitude (p < 0.03). The authors' conclusion was direct: diet and exercise counseling in impaired glucose tolerance results in cutaneous reinnervation (Smith et al., Diabetes Care, 2006).
A second study followed 100 patients with type 2 diabetes who did not yet have neuropathy. Sixty were assigned to structured supervised weekly exercise and forty to quarterly lifestyle counseling, for one year. Distal leg nerve fiber density rose by 1.5 fibers per millimeter in the exercise group and fell slightly in the counseling group (p = 0.03) (Singleton et al., Annals of Clinical and Translational Neurology, 2014).
These are modest effect sizes with wide standard deviations, and neither was a large trial. I am not going to inflate them. But they are the studies where the biopsy needle went back into human skin and counted more fibers than it found the first time. Nothing else in this article has done that.
Structured, supervised, weekly, for a year. That is the dose that moved nerve fiber density in human beings.
Here is what it translates to in practice.
Glucose excursions matter more than the average. Nerve tissue does not experience your A1C. It experiences the peaks. Two people with identical A1C values can have very different postprandial curves, and flatter curves usually mean better blood sugar control in patients with diabetes or prediabetes. It is the spikes that drive the polyol pathway, advanced glycation end product formation, and oxidative stress in nerve tissue. Practically, the shape of the meal matters: protein and fiber before starch, a ten-minute walk afterward, and a reduced refined carbohydrate load. The mechanism behind why high blood sugar damages nerves is worth reading in full.
The exercise dose that was actually studied. Not "stay active." The trials above used structured, supervised, moderate-intensity aerobic exercise, weekly, sustained across a full year. That is the dose that moved nerve fiber density, and it is worth knowing the real number rather than a vague instruction. Balance and gait training is a separate and worthwhile addition for anyone with proprioceptive loss or fall risk.
Dietary pattern. Mediterranean-style and lower-glycemic patterns carry the best supporting evidence here. In practice that means a diet built on vegetables and fruit, adequate fiber, and omega-3 fatty acids, with refined grains reduced rather than simply supplemented around. The goal is lower glycemic load and lower inflammatory burden at the same time.
Sleep, treated as a real variable. Chronic sleep disruption amplifies central sensitization, which increases the perceived intensity of neuropathic burning independent of anything happening at the fiber level. Burning feet also destroy sleep. That loop runs in both directions and is worth breaking deliberately rather than waiting for a pain drug to solve it.
Alcohol. Worth naming plainly. Alcohol is directly neurotoxic to peripheral nerves and is one of the more common unacknowledged contributors in patients who have been told their neuropathy is idiopathic.
✦ KEY TAKEAWAY — No medication described in this article has been shown to increase nerve fiber density in a living human being. Diet and exercise have, in two separate studies, within one year. That is the ceiling every prescription is working underneath, and it is the layer you control without a prescriber.
✦ The Layer Most Physicians Were Never Taught
Everything in this section is the highest-leverage work available to you, and it is also the part your prescriber has the least training in. Nutrition and lifestyle intervention are largely absent from medical school and residency. That is not a criticism of your doctor. It is a description of the curriculum.
I came at this from an unusual direction. I trained in exercise physiology and nutrition before medical school, not after it, and I stayed current with that literature across my entire surgical career. So when I look at a nerve, I am looking at both the anatomy I spent years operating on and the metabolic environment that anatomy has to survive in. If you are not sure which of these two layers your effort belongs in right now, or what testing would settle it, that is exactly what the free 10-minute call at the end of this article is for.
The Nutrient Layer: Where It Sits, and Why Dose Decides Everything
This is the layer patients ask about most and get the least useful information on, usually because the conversation starts with a product instead of with a target.
Every medication on this page acts on the pain signal. None of them act on mitochondrial function, oxidative load, antioxidant balance, or the metabolic environment the nerve is trying to survive in. That gap is the rationale for nutrient support, and it is a different target rather than a competing one. It is also why nutrient support belongs alongside a treatment plan, not instead of one.
The filter that matters is not the ingredient list. It is the dose. A great many products on this shelf contain the right compounds at fractions of the amounts used in the trials that generated the interest in them. An ingredient panel tells you what is in the bottle. It tells you nothing about whether the amount resembles anything that has ever been studied. Comparing the actual milligram amounts against published trial doses is the single most reliable thing a consumer can do, and it disqualifies a surprising number of products in about ninety seconds.
Here is what the evidence supports, stated at the level it deserves.
Alpha-lipoic acid is the most studied antioxidant in this space. The strongest data came from intravenous dosing at 600mg daily over roughly three weeks. Oral long-term data are more limited, and reviewers have characterized the evidence for sustained oral benefit as modest rather than settled. The R-isomer is the biologically active form, which matters when a label lists only total lipoic acid. My full guide to alpha-lipoic acid for neuropathy covers the trials, the dose, and R-ALA vs regular ALA.
Benfotiamine is a fat-soluble derivative of thiamine with substantially better tissue uptake than the water-soluble form. Clinical trials in diabetic neuropathy have reported symptomatic improvement, though the studies are generally small.
Methylcobalamin is the active coenzyme form of B12 and the form worth insisting on. The evidence for benefit is strongest where deficiency is actually documented, which is a good argument for measuring methylmalonic acid rather than assuming sufficiency from a serum B12 in the normal range. Functional deficiency hides behind a normal B12 more often than most patients realize, and I have written the full case for methylcobalamin over cyanocobalamin separately.
Acetyl-L-carnitine supports mitochondrial fatty acid transport in neurons, with trial data in diabetic neuropathy showing symptomatic improvement.
CoQ10 addresses electron transport chain function, with solid mechanistic rationale and thinner human data in neuropathy specifically. Worth including for the mechanism, worth describing honestly as less studied than the compounds above.
Curcumin is the one where formulation decides everything. Curcumin faces three absorption barriers at once: poor solubility in the gut, rapid hepatic metabolism through CYP3A4 and UGT enzymes, and active P-glycoprotein efflux pumping it back out of cells. Piperine, the black pepper extract, addresses the metabolic and efflux barriers and has been shown to raise curcumin bioavailability substantially (Shoba et al., 1998). Curcumin without a bioavailability strategy is largely a label ingredient. One caution: because piperine works partly by inhibiting CYP3A4, anyone taking medications metabolized through that pathway should raise it with their prescriber.
I formulate a nerve support supplement, NeuroAxis, built around these compounds at doses matched to the published literature, so treat that as a disclosed interest rather than a neutral recommendation. The more useful thing I can give you is the filter itself: whatever product you are considering, put its milligram amounts next to the trial doses above and see whether they line up.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
The One Place Where More Is Actively Worse
Vitamin B6 deserves its own warning. Pyridoxine at high doses is itself neurotoxic and can cause a sensory neuropathy, which means an aggressive B-complex can produce the exact symptom it was purchased to relieve. This is not theoretical and it is not rare. Formulations that keep B6 modest, in the range of 10mg, are making a deliberate safety decision, and it is worth checking the number on any product you are already taking.
These are structure and function considerations for supporting nerve and metabolic health. They are not treatments for neuropathy, they do not replace the workup, and they do not replace a conversation with your prescriber about the medication layer.
Your Treatment Timeline
Today
Write down which medications you have taken, the highest dose you reached, and how long you stayed there. Most people have never assembled this list, and it is the single most useful thing to walk into an appointment holding.
This Week
Start a simple 0 to 10 pain log, recording morning and evening scores, and use it to track whether treatment starts to relieve pain over time. Book the appointment. Start the after-meal ten-minute walk.
This Month
If a drug was abandoned during titration, discuss restarting it with a slower ramp. If you are at target dose with partial relief, discuss adding a second agent from a different class rather than switching. Get the aerobic exercise onto a fixed weekly schedule.
Long Term
Give each regimen a fair trial of six to eight weeks at target dose before judging it. Hold the metabolic work for a full year before deciding whether it moved anything, because that is the timeframe in which it was studied. Reassess the workup annually, because idiopathic sometimes turns out to mean not yet identified.
Frequently Asked Questions
What do I do when neuropathy medication doesn't work?
Check whether it was actually tested. Reaching a therapeutic dose takes two to four weeks of titration, and the result only means something after roughly four more weeks at that dose. If you stopped during the ramp, the drug has not failed. If you did complete a full trial, the next step is usually adding a second agent from a different class rather than swapping, and revisiting whether the underlying driver was ever identified. Keep expectations calibrated too: over the counter pain relievers do very little for neuropathic pain, which is why targeted nerve pain medications exist.
How long should I give a nerve pain medication before deciding?
Six to eight weeks total from starting: two to four weeks titrating to target, then four weeks holding there. Track pain on a written 0 to 10 scale, because a genuine 30 percent improvement is easy to miss from memory.
Can I take two neuropathy medications at once?
Combining classes has trial support and often works better at lower doses of each than pushing one drug to its limit. A gabapentinoid pairs reasonably with a tricyclic or a serotonin and norepinephrine reuptake inhibitor. The pairing to avoid outside specialist supervision is duloxetine with a tricyclic, because both raise serotonin.
Is IVIG worth asking about for small fiber neuropathy?
If your small fiber neuropathy is idiopathic, the randomized evidence says no. The first double-blind placebo-controlled trial found 40 percent of the IVIG group improved compared with 30 percent on saline, a difference that was not statistically significant. If a specific autoimmune disease has been confirmed as the driver, immunotherapy aimed at that disease is a legitimate conversation with your neurologist or rheumatologist.
Is scrambler therapy worth trying for neuropathy?
Possibly, in a refractory case, with clear expectations. The published small fiber neuropathy evidence is three patients with mixed results. Its safety profile is good, which is the main argument for trying it. The response rates circulating online come from other conditions.
How much exercise does it actually take to matter?
The studies that documented nerve fiber regrowth used structured, supervised, moderate-intensity aerobic exercise on a weekly schedule, sustained for a full year. That is a real commitment and it is worth stating honestly rather than softening into "stay active." The tradeoff is that it is the only intervention on this page with human evidence of increasing nerve fiber density.
When should I see a pain specialist rather than a neurologist?
A neurologist owns the diagnosis and the underlying-cause workup. Once two or more drug classes have failed at adequate doses and the driver has been identified and addressed as far as it can be, a pain specialist takes over the broader pain management question, including combination regimens, nerve blocks, and other interventional options when severe pain persists.
Do nerve supplements help small fiber neuropathy?
They target a different thing than your medication does. The drugs act on the pain signal; the nutrient layer is aimed at the metabolic and mitochondrial environment around the nerve. Individual compounds including alpha-lipoic acid, benfotiamine, methylcobalamin, and acetyl-L-carnitine have trial data, mostly in diabetic neuropathy and mostly in small studies. The deciding factor is almost always dose and form rather than whether the ingredient appears on the label. Check the milligram amounts against the published trial doses, and check that B6 is kept modest. My broader evidence review of whether nerve support supplements are effective goes further.
Do opioids help small fiber neuropathy?
They sit third-line in the guidelines and may be used to treat pain in some refractory cases, but efficacy in neuropathic pain is modest and the risk profile is significant. Long-term outcome data are poor. They do not address anything happening at the nerve.
Bringing This to Your Next Appointment
You do not need to argue with anyone. You need to walk in with two pieces of paper.
The first is your medication history: every drug tried, the highest dose reached, how long you held it, and why you stopped. That single list changes the conversation more than anything else you can bring, because it usually reveals that two of the three "failed" drugs were never given a real trial.
The second is your workup status: whether a two-hour glucose tolerance test, methylmalonic acid, an autoimmune screen, and a nerve fiber density biopsy have been done. Small fiber neuropathy damages the small nerve fibers of the peripheral nervous system, producing burning, tingling, and altered temperature sensation, and autonomic involvement can add symptoms that never get connected to the same diagnosis. A proper evaluation starts with history and physical examination, then uses skin biopsy and autonomic testing to confirm what the examination suggests. Celiac disease can produce this exact pattern, which is one more reason to identify the cause before committing to a treatment.
Effective small fiber neuropathy treatment is four things running at once. The driver identified and treated wherever that is possible. Medications optimized honestly, at real doses, for a real duration. The metabolic environment corrected, which is the layer with the most leverage and the least prescribing. And nutrient support built on doses that match the published literature rather than on what appears on a label.
The drugs manage what you feel. The rest of it is what determines what you are managing.
Next Steps for Your Nerve Health
If you have been cycling through prescriptions without a clear answer, the most useful next move is usually a conversation rather than another bottle. The free 10-minute call is the fastest way to work out which layer your effort belongs in. Once you know what you are treating, NeuroAxis is the formulation I built for the nutrient layer described above, and the Nerve Health Blueprint covers the rest in more depth than an article reasonably can.
Where to go from here
Explore NeuroAxis: the multi-pathway nerve support formula I developed, with the 160-page NeuroAxis Protocol included.*
Get the free Nerve Health Blueprint: my nutrition and lifestyle framework.
Book a free 10-minute discovery call: talk through your situation directly.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
About the Author
Dr. Michael Fitzmaurice, MD is a fellowship-trained peripheral nerve surgeon with a background in nerve physiology, metabolic health, and applied exercise physiology. Over a surgical career of more than 3,000 peripheral nerve procedures, he observed the close relationship between metabolic health, cellular energy production, and nervous system function. His work focuses on how physical activity, recovery biology, and nutrition-informed strategies relate to long-term nerve and metabolic health.
He oversees Dr. Fitz Nutrition, an education-first initiative translating evidence-informed research into thoughtfully designed formulations for nerve and metabolic health, and believes that patients who understand the science make better decisions about their care.
This content is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Medication dosing information is presented as published in the clinical literature and is not medical advice or a prescribing recommendation. Dr. Fitzmaurice formulates and has a financial interest in the nerve support supplement referenced above. Individual results vary. Always consult a qualified healthcare provider regarding your individual medical situation.